Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With <i>KRAS</i> Wild-Type Tumors in Metastatic Colorectal CancerDominik Paul Modest, Volker Heinemann, Alexander Kiani et al.|Journal of Clinical Oncology|2015Cited by 123
In vivo cancer-associated fibroblast specific gene silencing for anti-stromal therapy in primary liver cancer using novel siRNA loaded polypeptoide nanoparticlesPaul M. Schneider, Leonard Kaps, Leon Capelôa et al.|Journal of Hepatology|2023Cited by 0